Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies

Cancer Treatment Reviews

Volumn 38, Issue 7, 2012, Pages 890-903

  Murray, S ^a   Briasoulis, E ^b   Linardou, H ^c   Bafaloukos, D ^b   Papadimitriou, C ^d  

^a GeneKOR ^*  (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c METROPOLITAN HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

BRCA1 2; HER2; MRP 1; P glycoprotein; P53; Resistance; Stathmin; Taxane

Indexed keywords

BETA TUBULIN; COLCHICINE; DOCETAXEL; GLYCOPROTEIN P; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOTAXEN; PACLITAXEL; PACLITAXEL POLIGLUMEX; PACLITAXEL TOCOSOL; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; TAXANE DERIVATIVE; THERMODOX; TOCOSOL; TUMOR MARKER; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; DRUG FORMULATION; DRUG MECHANISM; GENE OVEREXPRESSION; HUMAN; LIPOSOMAL DELIVERY; M PHASE CELL CYCLE CHECKPOINT; MEDLINE; MICROTUBULE; NONHUMAN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; P-GLYCOPROTEIN; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84865407138     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.02.011     Document Type: Review

References (185)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. http://seer.cancer.gov/statfacts/html/breast.html.
3. King K.M., Lupichuk S., Baig L., Webster M., Basi S., Whyte D., et al. Optimal use of taxanes in metastatic breast cancer. Curr Oncol 2009, 16(3):8-20.
4. Chan S., Friedrichs K., Noel D., Pinter T., Van Belle S., Vorobiof D., et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999, 17(8):2341-2354.
5. Evans T.R., Yellowlees A., Foster E., Earl H., Cameron D.A., Hutcheon A.W., et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol 2005, 23(13):2988-2995.
6. Nabholtz J.M., Senn H.J., Bezwoda W.R., Melnychuk D., Deschenes L., Douma J., et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999, 17(5):1413-1424.
7. Jassem J., Pienkowski T., Pluzanska A., Jelic S., Gorbunova V., Mrsic-Krmpotic Z., et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001, 19(6):1707-1715.
8. Bedard P.L., Di Leo A., Piccart-Gebhart M.J. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol 2010, 7(1):22-36.
9. Palmieri C., Krell J., James C.R., Harper-Wynne C., Misra V., Cleator S., et al. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol 2010, 7(10):561-574.
10. Cardoso F., Senkus-Konefka E., Fallowfield L., Costa A., Castiglione M. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v15-19.
11. Gonzalez-Angulo A.M., Morales-Vasquez F., Hortobagyi G.N. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007, 608:1-22.
12. Pohlmann P.R., Mayer I.A., Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009, 15(24):7479-7491.
13. Zhao Y., Liu H., Liu Z., Ding Y., Ledoux S.P., Wilson G.L., et al. Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res 2011, 71(13):4585-4597.
14. Dalton W.S. Mechanisms of drug resistance in breast cancer. Semin Oncol 1990, 17(4 Suppl. 7):37-39.
15. Rottenberg S., Nygren A.O., Pajic M., van Leeuwen F.W., van der Heijden I., van de Wetering K., et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A 2007, 104(29):12117-12122.
16. O'Brien C., Cavet G., Pandita A., Hu X., Haydu L., Mohan S., et al. Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res 2008, 68(13):5380-5389.
17. Brooks T.A., Minderman H., O'Loughlin K.L., Pera P., Ojima I., Baer M.R., et al. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther 2003, 2(11):1195-1205.
18. Raguz S., Yague E. Resistance to chemotherapy: new treatments and novel insights into an old problem. Br J Cancer 2008, 99(3):387-391.
19. Ahmed-Belkacem A., Pozza A., Munoz-Martinez F., Bates S.E., Castanys S., Gamarro F., et al. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2. Cancer res 2005, 65(11):4852-4860.
20. Kuhnle M., Egger M., Muller C., Mahringer A., Bernhardt G., Fricker G., et al. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J Med Chem 2009, 52(4):1190-1197.
21. Yoshida N., Takada T., Yamamura Y., Adachi I., Suzuki H., Kawakami J. Inhibitory effects of terpenoids on multidrug resistance-associated protein 2- and breast cancer resistance protein-mediated transport. Drug Metab Dispos 2008, 36(7):1206-1211.
22. Bollag D.M., McQueney P.A., Zhu J., Hensens O., Koupal L., Liesch J., et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995, 55(11):2325-2333.
23. Rivera E., Lee J., Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist 2008, 13(12):1207-1223.
24. Farmer P., Bonnefoi H., Anderle P., Cameron D., Wirapati P., Becette V., et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009, 15(1):68-74.
25. Harris L.N., You F., Schnitt S.J., Witkiewicz A., Lu X., Sgroi D., et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007, 13(4):1198-1207.
26. Pandolfi P.P. Breast cancer-loss of PTEN predicts resistance to treatment. N Engl J Med 2004, 351(22):2337-2338.
27. Lee C.H., Macgregor P.F. Using microarrays to predict resistance to chemotherapy in cancer patients. Pharmacogenomics 2004, 5(6):611-625.
28. Linardou H., Briasoulis E., Dahabreh I.J., Mountzios G., Papadimitriou C., Papadopoulos S., et al. All about KRAS for clinical oncology practice. gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat Rev 2011, 37(3):221-233.
29. Joerger M., Huitema A.D., Richel D.J., Dittrich C., Pavlidis N., Briasoulis E., et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 2007, 13(21):6410-6418.
30. Thomas C., Gustafsson J.A. A CUE hints at tumor resistance. Nat Med 2011, 17(6):658-660.
31. Rowinsky E.K., Donehower R.C. Paclitaxel (taxol). N Engl J Med 1995, 332(15):1004-1014.
32. Thigpen J.T., Blessing J.A., Ball H., Hummel S.J., Barrett R.J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994, 12(9):1748-1753.
33. Einzig A.I. Review of phase II trials of Taxol (paclitaxel) in patients with advanced ovarian cancer. Ann Oncol 1994, 5(Suppl. 6):S29-32.
34. Fountzilas G., Athanassiades A., Giannakakis T., Bafaloukos D., Karakousis K., Dombros N., et al. A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines. Eur J Cancer 1996, 32A(1):47-51.
35. Wilson W.H., Berg S.L., Bryant G., Wittes R.E., Bates S., Fojo A., et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994, 12(8):1621-1629.
36. Millward M.J., Bishop J.F., Friedlander M., Levi J.A., Goldstein D., Olver I.N., et al. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 1996, 14(1):142-148.
37. Gatzemeier U., Heckmayr M., Neuhauss R., Schluter I., Pawel J.V., Wagner H., et al. Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung cancer 1995, 12(Suppl. 2):S101-106.
38. Papamichael D., Gallagher C.J., Oliver R.T., Johnson P.W., Waxman J. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer 1997, 75(4):606-607.
39. Ringel I., Horwitz S.B. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991, 83(4):288-291.
40. Gligorov J., Lotz J.P. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 2004, 9(Suppl. 2):3-8.
41. Parness J., Horwitz S.B. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981, 91(2 Pt 1):479-487.
42. Rao S., Orr G.A., Chaudhary A.G., Kingston D.G., Horwitz S.B. Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl)taxol photolabels a peptide (amino acids 217-231) of beta-tubulin. J Biol Chem 1995, 270(35):20235-20238.
43. Crossin K.L., Carney D.H. Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor. Cell 1981, 27(2 Pt 1):341-350.
44. Fabbri F., Carloni S., Brigliadori G., Zoli W., Lapalombella R., Marini M. Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: a cytometric study. BMC Cell Biol 2006, 7:6.
45. Ferlini C., Cicchillitti L., Raspaglio G., Bartollino S., Cimitan S., Bertucci C., et al. Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res 2009, 69(17):6906-6914.
46. Varbiro G., Veres B., Gallyas F. Sumegi B: direct effect of Taxol on free radical formation and mitochondrial permeability transition. Free Radic Biol Med 2001, 31(4):548-558.
47. Ibrado A.M., Kim C.N., Bhalla K. Temporal relationship of CDK1 activation and mitotic arrest to cytosolic accumulation of cytochrome C and caspase-3 activity during Taxol-induced apoptosis of human AML HL-60 cells. Leukemia 1998, 12(12):1930-1936.
48. Ling Y.H., Consoli U., Tornos C., Andreeff M., Perez-Soler R. Accumulation of cyclin B1, activation of cyclin B1-dependent kinase and induction of programmed cell death in human epidermoid carcinoma KB cells treated with taxol. Int J Cancer 1998, 75(6):925-932.
49. Yuan J., Kramer A., Matthess Y., Yan R., Spankuch B., Gatje R., et al. Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo. Oncogene 2006, 25(12):1753-1762.
50. Sudo T., Nitta M., Saya H., Ueno N.T. Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 2004, 64(7):2502-2508.
51. Berchem G.J., Bosseler M., Mine N., Avalosse B. Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2. Anticancer Res 1999, 19(1A):535-540.
52. Wang S., Wang Z., Boise L., Dent P., Grant S. Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis. Biochem Biophys Res Commun 1999, 259(1):67-72.
53. Jordan M.A., Toso R.J., Thrower D., Wilson L. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci U S A 1993, 90(20):9552-9556.
54. Rudner A.D., Murray A.W. The spindle assembly checkpoint. Curr Opin Cell Biol 1996, 8(6):773-780.
55. Long B.H., Fairchild C.R. Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res 1994, 54(16):4355-4361.
56. Wang J., Lou P., Lesniewski R., Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003, 14(1):13-19.
57. Wang T.H., Wang H.S., Soong Y.K. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000, 88(11):2619-2628.
58. Gottesman M.M., Hrycyna C.A., Schoenlein P.V., Germann U.A., Pastan I. Genetic analysis of the multidrug transporter. Annu Rev Genet 1995, 29:607-649.
59. Baldini N. Multidrug resistance-a multiplex phenomenon. Nat Med 1997, 3(4):378-380.
60. Lee A.J., Endesfelder D., Rowan A.J., Walther A., Birkbak N.J., Futreal P.A., et al. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res 2011, 71(5):1858-1870.
61. Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C., Gomer C.J., et al. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res 2001, 61(16):6185-6193.
62. Marquardt D., McCrone S., Center M.S. Mechanisms of multidrug resistance in HL60 cells: detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein. Cancer Res 1990, 50(5):1426-1430.
63. Keizer H.G., Schuurhuis G.J., Broxterman H.J., Lankelma J., Schoonen W.G., van Rijn J., et al. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res 1989, 49(11):2988-2993.
64. Zhu W., Shan X., Wang T., Shu Y., Liu P. MiR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010, 127(11):2520-2529.
65. Ling V. Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugs. Cancer 1992, 69(10):2603-2609.
66. Schinkel A.H. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 1997, 8(3):161-170.
67. Cordon-Cardo C., O'Brien J.P., Boccia J., Casals D., Bertino J.R., Melamed M.R. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990, 38(9):1277-1287.
68. Trock B.J., Leonessa F., Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997, 89(13):917-931.
69. Beck W.T., Grogan T.M., Willman C.L., Cordon-Cardo C., Parham D.M., Kuttesch J.F., et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996, 56(13):3010-3020.
70. Dean M., Rzhetsky A., Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001, 11(7):1156-1166.
71. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002, 2(1):48-58.
72. Fojo A.T., Menefee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin Oncol 2005, 32(6 Suppl. 7):S3-8.
73. Szakacs G., Annereau J.P., Lababidi S., Shankavaram U., Arciello A., Bussey K.J., et al. Predicting drug sensitivity and resistance. profiling ABC transporter genes in cancer cells. Cancer cell 2004, 6(2):129-137.
74. Kruh G.D., Belinsky M.G. The MRP family of drug efflux pumps. Oncogene 2003, 22(47):7537-7552.
75. Gandhi Y.A., Morris M.E. Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2). Aaps J 2009, 11(3):541-552.
76. Mao Q., Unadkat J.D. Role of the breast cancer resistance protein (ABCG2) in drug transport. Aaps J 2005, 7(1):E118-133.
77. Sanfilippo O., Ronchi E., De Marco C., Di Fronzo G., Silvestrini R. Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Eur J Cancer 1991, 27(2):155-158.
78. Clarke R., Leonessa F., Trock B. Multidrug resistance/P-glycoprotein and breast cancer: review and meta-analysis. Semin Oncol 2005, 32(6 Suppl. 7):S9-15.
79. Merkel D.E., Fuqua S.A., McGuire W.L. P-glycoprotein in breast cancer. Cancer Treat Res 1989, 48:97-105.
80. Bell D.R., Trent J.M., Willard H.F., Riordan J.R., Ling V. Chromosomal location of human P-glycoprotein gene sequences. Cancer Genet Cytogenet 1987, 25(1):141-148.
81. Osborn M., Weber K. The display of microtubules in transformed cells. Cell 1977, 12(3):561-571.
82. Saito S.Y. Toxins affecting actin filaments and microtubules. Prog Mol Subcell Biol 2009, 46:187-219.
83. Wade R.H. Microtubules: an overview. Methods Mol Med 2007, 137:1-16.
84. Kerssemakers J.W., Munteanu E.L., Laan L., Noetzel T.L., Janson M.E., Dogterom M. Assembly dynamics of microtubules at molecular resolution. Nature 2006, 442(7103):709-712.
85. Dumontet C., Sikic B.I. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999, 17(3):1061-1070.
86. Mitchison T., Kirschner M. Dynamic instability of microtubule growth. Nature 1984, 312(5991):237-242.
87. Dutcher S.K. The tubulin fraternity: alpha to eta. Curr Opin Cell Biol 2001, 13(1):49-54.
88. Stearns T., Evans L., Kirschner M. Gamma-tubulin is a highly conserved component of the centrosome. Cell 1991, 65(5):825-836.
89. Verhey K.J., Gaertig J. The tubulin code. Cell Cycle 2007, 6(17):2152-2160.
90. Snyder J.P., Nettles J.H., Cornett B., Downing K.H., Nogales E. The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci U S A 2001, 98(9):5312-5316.
91. Yusuf R.Z., Duan Z., Lamendola D.E., Penson R.T., Seiden M.V. Paclitaxel resistance. molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003, 3(1):1-19.
92. Han E.K., Gehrke L., Tahir S.K., Credo R.B., Cherian S.P., Sham H., et al. Modulation of drug resistance by alpha-tubulin in paclitaxel-resistant human lung cancer cell lines. Eur J Cancer 2000, 36(12):1565-1571.
93. Minotti A.M., Barlow S.B., Cabral F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 1991, 266(6):3987-3994.
94. Rouzier R., Rajan R., Wagner P., Hess K.R., Gold D.L., Stec J., et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A 2005, 102(23):8315-8320.
95. Giannakakou P., Sackett D.L., Kang Y.K., Zhan Z., Buters J.T., Fojo T., et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997, 272(27):17118-17125.
96. Kirschner M.W. Microtubule assembly and nucleation. Int Rev Cytol 1978, 54:1-71.
97. Banerjee A., Roach M.C., Trcka P., Luduena R.F. Preparation of a monoclonal antibody specific for the class IV isotype of beta-tubulin. Purification and assembly of alpha beta II, alpha beta III, and alpha beta IV tubulin dimers from bovine brain. J Biol Chem 1992, 267(8):5625-5630.
98. Derry W.B., Wilson L., Khan I.A., Luduena R.F., Jordan M.A. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry 1997, 36(12):3554-3562.
99. Lu Q., Luduena R.F. Removal of beta III isotype enhances taxol induced microtubule assembly. Cell Struct Funct 1993, 18(3):173-182.
100. Varna M., Lehmann-Che J., Turpin E., Marangoni E., El-Bouchtaoui M., Jeanne M., et al. P53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors. Int J Cancer 2009, 124(4):991-997.
101. Chevillard S., Lebeau J., Pouillart P., de Toma C., Beldjord C., Asselain B., et al. Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy. Clin Cancer Res 1997, 3(12 Pt 1):2471-2478.
102. Delia D., Mizutani S., Lamorte G., Goi K., Iwata S., Pierotti M.A. P53 activity and chemotherapy. Nat Med 1996, 2(7):724-725.
103. Wattel E., Preudhomme C., Hecquet B., Vanrumbeke M., Quesnel B., Dervite I., et al. P53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994, 84(9):3148-3157.
104. Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006, 97(9):813-820.
105. Vasey P.A., Jones N.A., Jenkins S., Dive C., Brown R. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol 1996, 50(6):1536-1540.
106. Huang Y., Ibrado A.M., Reed J.C., Bullock G., Ray S., Tang C., et al. Co-expression of several molecular mechanisms of multidrug resistance and their significance for paclitaxel cytotoxicity in human AML HL-60 cells. Leukemia 1997, 11(2):253-257.
107. Strobel T., Swanson L., Korsmeyer S., Cannistra S.A. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci U S A 1996, 93(24):14094-14099.
108. Wang Z., Goulet R., Stanton K.J., Sadaria M., Nakshatri H. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel. Anticancer Res 2005, 25(3c):2367-2379.
109. Ganta S., Amiji M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 2009, 6(3):928-939.
110. Mabuchi S., Ohmichi M., Nishio Y., Hayasaka T., Kimura A., Ohta T., et al. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res 2004, 10(22):7645-7654.
111. Coloff J.L., Macintyre A.N., Nichols A.G., Liu T., Gallo C.A., Plas D.R., et al. Akt-dependent glucose metabolism promotes mcl-1 synthesis to maintain cell survival and resistance to bcl-2 inhibition. Cancer Res 2011, 71(15):5204-5213.
112. Bratton M.R., Duong B.N., Elliott S., Weldon C.B., Beckman B.S., McLachlan J.A., et al. Regulation of ERalpha-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: implications for breast cancer cell survival. Int J Oncol 2010, 37(3):541-550.
113. Wang X., Yi L., Zhu Y., Zou J., Hong Y., Zheng W. AKT signaling pathway in invasive ductal carcinoma of the breast: correlation with ERa, ERbeta and HER-2 expression. Tumori 2011, 97(2):185-190.
114. Knuefermann C., Lu Y., Liu B., Jin W., Liang K., Wu L., et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003, 22(21):3205-3212.
115. Sastre-Garau X., Genin P., Rousseau A., Al Ghuzlan A., Nicolas A., Freneaux P., et al. Increased cell size and Akt activation in HER-2/neu-overexpressing invasive ductal carcinoma of the breast. Histopathology 2004, 45(2):142-147.
116. Skoufias D.A., Andreassen P.R., Lacroix F.B., Wilson L., Margolis R.L. Mammalian mad2 and bub1/bubR1 recognize distinct spindle-attachment and kinetochore-tension checkpoints. Proc Natl Acad Sci U S A 2001, 98(8):4492-4497.
117. Takahashi T., Yamasaki F., Sudo T., Itamochi H., Adachi S., Tamamori-Adachi M., et al. Cyclin A-associated kinase activity is needed for paclitaxel sensitivity. Mol Cancer Ther 2005, 4(7):1039-1046.
118. Chabalier C., Lamare C., Racca C., Privat M., Valette A., Larminat F. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 2006, 5(9):1001-1007.
119. Egawa C., Miyoshi Y., Takamura Y., Taguchi T., Tamaki Y., Noguchi S. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer. Int J Cancer 2001, 95(4):255-259.
120. Alli E., Yang J.M., Ford J.M., Hait W.N. Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol Pharmacol 2007, 71(5):1233-1240.
121. Chuthapisith S., Layfield R., Kerr I.D., Hughes C., Eremin O. Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int J Oncol 2007, 30(6):1545-1551.
122. Yu D., Jing T., Liu B., Yao J., Tan M., McDonnell T.J., et al. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 1998, 2(5):581-591.
123. Tan M., Jing T., Lan K.H., Neal C.L., Li P., Lee S., et al. Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell 2002, 9(5):993-1004.
124. Chang J.C., Wooten E.C., Tsimelzon A., Hilsenbeck S.G., Gutierrez M.C., Elledge R., et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003, 362(9381):362-369.
125. Iwao-Koizumi K., Matoba R., Ueno N., Kim S.J., Ando A., Miyoshi Y., et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 2005, 23(3):422-431.
126. Liu B., Sun D., Xia W., Hung M.C., Yu D. Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1). J Natl Cancer Inst 1997, 89(20):1524-1529.
127. Mechetner E., Kyshtoobayeva A., Zonis S., Kim H., Stroup R., Garcia R., et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 1998, 4(2):389-398.
128. Trock B.J., Hilakivi-Clarke L., Clarke R. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst 2006, 98(7):459-471.
129. Fujita T., Ito K., Izumi H., Kimura M., Sano M., Nakagomi H., et al. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel. Clin Cancer Res 2005, 11(24 Pt 1):8837-8844.
130. Orr G.A., Verdier-Pinard P., McDaid H., Horwitz S.B. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003, 22(47):7280-7295.
131. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010, 10(3):194-204.
132. Berrieman H.K., Lind M.J., Cawkwell L. Do beta-tubulin mutations have a role in resistance to chemotherapy?. Lancet Oncol 2004, 5(3):158-164.
133. Bernard-Marty C., Treilleux I., Dumontet C., Cardoso F., Fellous A., Gancberg D., et al. Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin Breast Cancer 2002, 3(5):341-345.
134. Hasegawa S., Miyoshi Y., Egawa C., Ishitobi M., Taguchi T., Tamaki Y., et al. Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 2003, 9(8):2992-2997.
135. Smoter M., Bodnar L., Duchnowska R., Stec R., Grala B., Szczylik C. The role of Tau protein in resistance to paclitaxel. Cancer Chemother Pharmacol 2011, 68(3):553-557.
136. Comen E., Davids M., Kirchhoff T., Hudis C., Offit K., Robson M. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women. Breast Cancer Res Treat 2011, 129(1):185-190.
137. Chang H.R., Glaspy J., Allison M.A., Kass F.C., Elashoff R., Chung D.U., et al. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer 2010, 116(18):4227-4237.
138. Wang S., Shi Y., Yuan Z., Wang X., Liu D., Peng R., et al. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens. Med Oncol 2011.
139. Wysocki P.J., Korski K., Lamperska K., Zaluski J., Mackiewicz A. Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations. Med Sci Monit 2008, 14(7):SC7-10.
140. Juul N., Szallasi Z., Eklund A.C., Li Q., Burrell R.A., Gerlinger M., et al. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. Lancet Oncol 2010, 11(4):358-365.
141. Yu D. Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. Semin Oncol 2001, 28(5 Suppl. 16):12-17.
142. Pegram M.D., Finn R.S., Arzoo K., Beryt M., Pietras R.J., Slamon D.J. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997, 15(5):537-547.
143. Jarvinen T.A., Liu E.T. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes-molecular basis for combination chemotherapy in cancer. Curr Cancer Drug Targets 2006, 6(7):579-602.
144. Arriola E., Marchio C., Tan D.S., Drury S.C., Lambros M.B., Natrajan R., et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 2008, 88(5):491-503.
145. Jarvinen T.A., Tanner M., Barlund M., Borg A., Isola J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999, 26(2):142-150.
146. Andre F., Mazouni C., Liedtke C., Kau S.W., Frye D., Green M., et al. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat 2008, 108(2):183-190.
147. Lee J.J., Swain S.M. Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR). Semin Oncol 2005, 32:S22-S26.
148. Schneider J., Lucas R., Sanchez J., Ruibal A., Tejerina A., Martin M. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP. Anticancer Res 2000, 20:4373-4377.
149. Filipits M., Pohl G., Rudas M., Dietze O., Las X., Grill R., et al. Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. JClin Oncol 2005, 23:1161-1168.
150. Perez E.A. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 2008, 8:2086-2095.
151. Rivera E., Fomez H. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res 2010, 12(Suppl. 2):S2.
152. Thomas E., Taberon J., Fornier M., Conte P., Furnoleau P., Lluch A., et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007, 25:3399-3406.
153. Perez E.A., Lerzo G., Pivot X., Thomas E., Vahdat L., Bossserman L., et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007, 25:3407-3414.
154. Bunnel C., Vahdat L., Schwatzberg L., Gralow J., Klimovsky J., Poulart V., et al. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer 2008, 8:234-241.
155. Cleator S., Heller W., Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007, 8:235-244.
156. Thomas E. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007, 25:5210-5217.
157. Valero V., Jones S.E., Von Hoff D.D., Booser D.J., Mennel R.G., Ravdin P.M., et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998, 16(10):3362-3368.
158. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5(3):219-234.
159. Arai T., Miyoshi Y., Kim S.J., Akazawa K., Maruyama N., Taguchi T., et al. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers. Eur J Surg Oncol 2008, 34(7):734-738.
160. Soussi T., Ishioka C., Claustres M., Beroud C. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer 2006, 6(1):83-90.
161. Vincent-Salomon A., Rousseau A., Jouve M., Beuzeboc P., Sigal-Zafrani B., Freneaux P., et al. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer 2004, 40(10):1502-1508.
162. Daidone M.G., Silvestrini R. Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer. J Natl Cancer Inst Monogr 2001, 30:27-35.
163. Amadori D., Volpi A., Maltoni R., Nanni O., Amaducci L., Amadori A., et al. Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study. Breast Cancer Res Treat 1997, 43(1):7-14.
164. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357(26):2666-2676.
165. Sledge G.W., Neuberg D., Bernardo P., Ingle J.N., Martino S., Rowinsky E.K., et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003, 21(4):588-592.
166. Bishop JF, Dewar J, Toner G, Tattersall MH, Olver I, Ackland S, et al. A randomized study of paclitaxel versus cyclophosphamide/methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer: preliminary results. Taxol Investigational Trials Group, Australia/New Zealand. Semin Oncol 1997; 24(5 Suppl 17): S17-15-S17-19.
167. Stemmler H.J., Harbeck N., Groll de Rivera I., Vehling Kaiser U., Rauthe G., Abenhardt W., et al. Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer. Oncology 2010, 79(3-4):204-210.
168. Joensuu H., Sailas L., Alanko T., Sunela K., Huuhtanen R., Utriainen M., et al. Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial. Ann Oncol 2010, 21(5):968-973.
169. Robert N., Leyland-Jones B., Asmar L., et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006, 24:2786-2792.
170. Pegram M., Forbes J., Pienkowski T., et al. BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol 2007, 25:968S.
171. Marty M., Cognetti F., Maraninchi D., et al. Superior long-term survival benefits of trastuzumab plus docetaxel compared to docetaxel alone in patients with HER2-positive metastatic breast cancer: patients surviving more than 4 years in the M77001 study. Breast Cancer Res Treat 2006, 100(Suppl. 1):S103.
172. Kim S.J., Miyoshi Y., Taguchi T., Tamaki Y., Nakamura H., Yodoi J., et al. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin Cancer Res 2005, 11(23):8425-8430.
173. Martin M., Romero A., Cheang M.C., Lopez Garcia-Asenjo J.A., Garcia-Saenz J.A., Oliva B., et al. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Res Treat 2011, 128(1):127-136.
174. Sankaran S., Starita L.M., Groen A.C., Ko M.J., Parvin J.D. Centrosomal microtubule nucleation activity is inhibited by BRCA1-dependent ubiquitination. Mol Cell Biol 2005, 25(19):8656-8668.
175. Estevez L.G., Cuevas J.M., Anton A., Florian J., Lopez-Vega J.M., Velasco A., et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 2003, 9(2):686-692.
176. Miyoshi Y., Kim S.J., Akazawa K., Kamigaki S., Ueda S., Yanagisawa T., et al. Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers. Clin Cancer Res 2004, 10(24):8163-8169.
177. Modi S., DiGiovanna M.P., Lu Z., Moskowitz C., Panageas K.S., Van Poznak C., et al. Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest 2005, 23(6):483-487.
178. Sjostrom J., Collan J., von Boguslawski K., Franssila K., Bengtsson N.O., Mjaaland I., et al. C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer. Eur J Cancer 2002, 38(4):535-542.
179. Gonzalez-Angulo A.M., Krishnamurthy S., Yamamura Y., Broglio K.R., Pusztai L., Buzdar A.U., et al. Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 2004, 101(2):258-263.
180. Camerini A., Donati S., Viacava P., Siclari O., Puccetti C., Tartarelli G., et al. Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer. J Exp Clin Cancer Res 2011, 30:38.
181. Di Leo A., Chan S., Paesmans M., Friedrichs K., Pinter T., Cocquyt V., et al. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat 2004, 86(3):197-206.
182. Luftner D., Henschke P., Flath B., Akrivakis C., Schnabel S., Prinz B., et al. Serum HER-2/neu as a prediction and monitoring parameter in a phase II study with weekly paclitaxel in metastatic breast cancer. Anticancer Res 2004, 24(2B):895-906.
183. Ooe A., Kato K., Noguchi S. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers. Breast Cancer Res Treat 2007, 101(3):305-315.
184. Chrisanthar R., Knappskog S., Lokkevik E., Anker G., Ostenstad B., Lundgren S., et al. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS One 2011, 6(4):e19249.
185. Maeno K., Ito K., Hama Y., Shingu K., Kimura M., Sano M., et al. Mutation of the class I beta-tubulin gene does not predict response to paclitaxel for breast cancer. Cancer Lett 2003, 198(1):89-97.